electroCore
ECOR | NASDAQ
$4.84
-$0.41 (-7.81%)
At close: Nov 16, 2026, 4:00 PM ET
$4.90
+$0.06 (+1.24%)
After-hours:
Nov 16, 2026, 7:30 PM ET
electroCore Company Profile
Company profile explainedCompany Profile
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Joshua S. Lev | CFO, Interim CEO, President & Director |
| Michael Fox | COO, Interim CEO, Interim President & Director |
| Amanda Yanuklis | Chief of Staff |
| Andy Brown | Vice President & Corporate Controller |
| Jennifer A. Hayes | Vice President of HR & Employee Success |
| Mitch Deshon | Vice President of Sales & New Market Development |
| Peter S. Staats | Chief Medical Officer |
| Thomas J. Errico | Founder & Independent Chairman |
electroCore
| Country | United States |
| IPO Date | Jun 22, 2018 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 83 |
| CEO | Joshua Lev |
Contact Details
200 Forge Way Rockaway,
New Jersey 07866 United States
Stock Details
| Ticker Symbol | ECOR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001560258 |
| CUSIP Number | 28531P202 |
| ISIN Number | US28531P2020 |
| SIC Code | 3845 |
Add to Watchlist
Select watchlists to add or remove ECOR